Purpose
The Director, HEOR Strategy, Immunology Pipeline leads the development and execution of the integrated HEOR evidence strategy for dermatology pipeline and select rheumatology pipeline assets. Aligns evidence plans with cross-functional asset strategies to advance pipeline assets across all development phases (Ph1 – Ph3). Drives clinical outcomes assessment strategy to secure label-enabling endpoints, generates robust real-world evidence to inform asset development and differentiation, and guides economic value assessments to support access and reimbursement globally. Demonstrates strong cross-functional leadership to influence and align HEOR strategies with matrix teams with the goal of developing compelling product value propositions that drive impact. The Director also uses his/her expertise to build evidence roadmaps that shape long-term disease area strategies and strengthen future portfolio impact.
This role could be based in any of locations within the US; Lake County, IL/Cambridge, MA/ Irvine, CA or Florham, NJ
Responsibilities
- Lead HEOR Strategy in development of end-to-end holistic evidence strategy for immunology (rheumatology and dermatology) assets from early proof of concept through Ph3 development, aligning evidence plans with asset differentiation, labeling, and global access objectives.
- Drive matrix decision-making through Pipeline Commercialization Model (PCM), aligning with and influencing clinical development, medical, regulatory, market access, and commercial stakeholders to navigate trade-offs and drive timely, evidence-based decisions.
- Lead Clinical Outcomes Assessment (COA) strategy: select, validate, and operationalize PROs/COAs in trials aligned with asset strategy; engage regulators on endpoint acceptability; and pursue label-enabling claims and differentiation.
- Drive real-world evidence (RWE) generation to inform trial design and target populations, unmet treatment needs, disease burden, patient journey, and future asset value across stakeholders.
- Guide economic value assessments (e.g., cost-effectiveness, budget impact, pricing scenarios, health-state utilities) to define product value, support pricing and reimbursement, and shape asset value narratives.
- Provide leadership in development of early integrated value propositions, creation of value frameworks/narratives, and conduct of affiliate touchpoint engagements to shape asset strategy and evidence generation plans to meet global stakeholder needs
- In collaboration with market access, provide HEOR leadership in development of global value dossiers, HTA strategies, access evidence gap closure plans, scenario analyses, and advisory engagements to anticipate and address payer requirements.
- Shape TA disease area strategies via identification and development of compelling evidence and novel endpoints to anticipate future asset value demonstration needs across stakeholders
- Effectively communicates the findings and strategic impact of research findings to internal (Executive Leadership, Area VPs, GMs etc.) and external (e.g., HTAs/Payors, patient (advocacy groups) and KOLs etc.) audiences